title: Sixth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin lymphoma.
authors.affiliation: Cochrane Haematological Malignancies Group Department of Internal Medicine 1, University Hospital of Cologne, Kerpener Street 62, D-50924 Cologne, Germany. olaf.weingart@uk-koeln.de
authors.forename: Olaf
authors.initials: O
authors.lastname: Weingart
authors.forename: Fareed A
authors.initials: FA
authors.lastname: Rehan
authors.forename: Holger
authors.initials: H
authors.lastname: Schulz
authors.forename: Frauke
authors.initials: F
authors.lastname: Naumann
authors.forename: Ina
authors.initials: I
authors.lastname: Knauel
authors.forename: Corinne Brillant Julia
authors.initials: CB
authors.lastname: Bohlius
authors.forename: Andreas
authors.initials: A
authors.lastname: Engert
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D019337:Hematologic Neoplasms / Q000188:drug therapy; D006801:Humans; D016393:Lymphoma, B-Cell / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab